Actively Recruiting

Phase 3
Age: 18Years - 70Years
All Genders
ID06082180

A Prospective, Open-label, Multicenter, Randomized Controlled Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer

Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2023-10-13

1199

Participants Needed

1

Research Sites

78 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the benefits and risks of prophylactic central lymph node dissection in patients with low-risk papillary thyroid carcinoma (PTC), specifically in those with primary tumors classified as cT1b-T2N0. PTC is the most common thyroid cancer, usually treated with surgery, but the need for removing lymph nodes that do not show obvious cancer involvement remains unclear. This study aims to clarify whether routine removal of these lymph nodes improves treatment response, reduces recurrence, and helps guide decisions about radioactive iodine therapy, while considering the risk of complications. The study randomly assigns participants to one of two groups: one group undergoes prophylactic central neck dissection on the side of the lesion, and the other group does not receive central neck dissection. Surgery is the primary intervention, and the trial is open-label and multicenter. The study includes adult patients aged 18 to 70 years with specific tumor sizes and no suspicious lymph nodes detected before surgery. Participants will be followed for at least one year to assess treatment response, measured by excellent response rates, and recurrence-free survival at one and two years. Assessments include monitoring thyroglobulin and its antibodies to evaluate short-term treatment outcomes. Study visits and follow-up tests will help track disease status and safety. The total participation duration is expected to cover these time points, supporting evaluation of long-term benefits and risks of the surgical approach.

CONDITIONS

Brief Title

A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 18 to 70 years with ECOG score 0-2
  • Thyroid nodule measuring 11-40 mm on ultrasound (cT1b-T2) confirmed as papillary thyroid carcinoma by biopsy or intraoperative frozen section
  • No suspicious lymph nodes on preoperative ultrasound (cN0) and no gross extrathyroidal extension
  • No serious medical diseases or dysfunction of major organs including blood, liver, kidney, heart, and lungs
  • No history of other head and neck malignancies, neck radiation, or deep neck surgery except skin mass resection
  • Able to understand, sign, and comply with study visits and procedures
Not Eligible

You will not qualify if you...

  • History of other malignancies except curable non-melanoma skin cancer and cervical carcinoma in situ
  • Tumors larger than 40 mm (cT3) or smaller than or equal to 10 mm
  • Tumors with suspected or obvious extrathyroidal extension
  • Metastatic or suspicious neck lymph nodes on ultrasound or during surgery (cN1)
  • No papillary thyroid carcinoma on biopsy or presence of high-risk PTC subtype
  • Pregnant or breastfeeding women
  • Participation in another therapeutic clinical trial within four months before study entry

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surgery and Immediate Post-operative Care

Duration - Day of surgery plus immediate recovery period

Participants undergo surgery where some receive prophylactic central neck dissection while others do not.

1 surgery visit and several immediate post-operative visits

Post-operative Follow-up

Duration - Up to 2 years

Participants are monitored for outcomes such as excellent response and recurrence-free survival.

Regular follow-up visits over 1 to 2 years

Trial Site Locations

Total: 1 location

1

Cancer Hospital, Chinese Academy of Medical Science

Beijing, Beijing Municipality, China, 100021

Actively Recruiting

Loading map...

Research Team

J

jie liu

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

177Lu-CTR-FAPI for the Treatment of Thyroid Cancer: A Multi-...

Thyroid Cancer

Actively Recruiting

2 locations

Active 24 Hours Subperiostal vs. Passive Subdural Drainage A...

Chronic Subdural Hematoma

Actively Recruiting

4 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here